iBio, Inc. (IBIO): Price and Financial Metrics
GET POWR RATINGS... FREE!
IBIO POWR Grades
- Momentum is the dimension where IBIO ranks best; there it ranks ahead of 41.53% of US stocks.
- The strongest trend for IBIO is in Growth, which has been heading up over the past 179 days.
- IBIO ranks lowest in Quality; there it ranks in the 1st percentile.
IBIO Stock Summary
- IBIO's price/sales ratio is 62.29; that's higher than the P/S ratio of 96.69% of US stocks.
- As for revenue growth, note that IBIO's revenue has grown -29.86% over the past 12 months; that beats the revenue growth of only 5.6% of US companies in our set.
- The volatility of iBio Inc's share price is greater than that of 95.09% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to iBio Inc, a group of peers worth examining would be BDR, MBII, RNLX, APPN, and DIOD.
- IBIO's SEC filings can be seen here. And to visit iBio Inc's official web site, go to www.ibioinc.com.
IBIO Valuation Summary
- In comparison to the median Healthcare stock, IBIO's price/sales ratio is 2326.32% higher, now standing at 92.2.
- IBIO's price/sales ratio has moved up 59.3 over the prior 144 months.
- IBIO's price/sales ratio has moved up 59.3 over the prior 144 months.
Below are key valuation metrics over time for IBIO.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
IBIO | 2021-08-31 | 92.2 | 2.6 | -10.2 | -9.2 |
IBIO | 2021-08-30 | 92.2 | 2.6 | -10.2 | -9.2 |
IBIO | 2021-08-27 | 92.2 | 2.6 | -10.2 | -9.2 |
IBIO | 2021-08-26 | 88.6 | 2.5 | -9.8 | -8.8 |
IBIO | 2021-08-25 | 91.5 | 2.6 | -10.1 | -9.1 |
IBIO | 2021-08-24 | 91.5 | 2.6 | -10.1 | -9.1 |
IBIO Growth Metrics
- Its 3 year net cashflow from operations growth rate is now at -100.68%.
- The 2 year revenue growth rate now stands at 162.6%.
- Its 4 year price growth rate is now at -78.31%.

The table below shows IBIO's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2021-12-31 | 1.635 | -34.608 | -28.621 |
2021-09-30 | 2.172 | -32.341 | -24.873 |
2021-06-30 | 2.371 | -30.064 | -23.467 |
2021-03-31 | 3 | -26.705 | -27.121 |
2020-12-31 | 2.331 | -23.142 | -24.137 |
2020-09-30 | 1.94 | -18.128 | -41.33 |
IBIO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- IBIO has a Quality Grade of D, ranking ahead of 5.38% of graded US stocks.
- IBIO's asset turnover comes in at 0.017 -- ranking 375th of 681 Pharmaceutical Products stocks.
- COLL, COCP, and IRWD are the stocks whose asset turnover ratios are most correlated with IBIO.
The table below shows IBIO's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.017 | 0.383 | -0.256 |
2021-03-31 | 0.024 | 0.836 | -0.331 |
2020-12-31 | 0.023 | 1.000 | -0.317 |
2020-09-30 | 0.027 | 1.000 | -0.273 |
2020-06-30 | 0.032 | 1.000 | -0.231 |
2020-03-31 | 0.036 | 1.000 | -0.271 |
IBIO Stock Price Chart Interactive Chart >
IBIO Price/Volume Stats
Current price | $0.23 | 52-week high | $1.76 |
Prev. close | $0.23 | 52-week low | $0.22 |
Day low | $0.23 | Volume | 1,833,100 |
Day high | $0.25 | Avg. volume | 2,260,444 |
50-day MA | $0.35 | Dividend yield | N/A |
200-day MA | $0.67 | Market Cap | 50.83M |
iBio, Inc. (IBIO) Company Bio
iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. Its pipeline include idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. It operates through the iBio, Inc. and iBio CDMO business segments. The company was founded on April 15, 1993 and is headquartered in New York, NY.
Latest IBIO News From Around the Web
Below are the latest news stories about iBio Inc that investors may wish to consider to help them evaluate IBIO as an investment opportunity.
iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate UpdateBRYAN, Texas, Feb. 14, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today announces its financial results for the fiscal quarter ended December 31, 2021 and provides a corporate update. “We are pleased to report that we have now added six new immuno-oncology assets to our pipeline in the six months since we announced our new drug discovery capabiliti |
iBio Q2 2022 Earnings PreviewiBio (NYSE:IBIO) is scheduled to announce Q2 earnings results on Monday, February 14th, after market close. The consensus EPS Estimate is -$0.04 (flat Y/Y) and the consensus Revenue Estimate is $0.25M (-64.8% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward. Revenue estimates... |
iBio to Report Fiscal 2022 Second Quarter Financial Results and Provide Corporate Update on Monday, February 14, 2022BRYAN, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, announced today that it will report its fiscal 2022 second quarter financial results after market close on Monday, February 14, 2022. iBio management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. |
iBio Advances Its Vaccine Program for Multi-Variant COVID-19 DiseaseiBio Inc (NYSE: IBIO ) received the FDA response to its pre-investigational new drug (IND) package for IBIO-202, the Company''s lead COVID-19 vaccine program. In light of the feedback received, the Company is moving forward with IND-enabling challenge studies for its second-generation … Full story available on Benzinga.com |
iBio provides update on COVID-19 vaccine program IBIO-202iBio < |
IBIO Price Returns
1-mo | -31.49% |
3-mo | -32.45% |
6-mo | -65.90% |
1-year | -83.21% |
3-year | -71.25% |
5-year | -93.78% |
YTD | -58.11% |
2021 | -47.71% |
2020 | 321.69% |
2019 | -66.80% |
2018 | -57.63% |
2017 | -55.75% |
Continue Researching IBIO
Want to do more research on iBio Inc's stock and its price? Try the links below:iBio Inc (IBIO) Stock Price | Nasdaq
iBio Inc (IBIO) Stock Quote, History and News - Yahoo Finance
iBio Inc (IBIO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...